Ocular herpes, mostly affected by the herpes simplex virus type 1 (HSV-1) and varicella-zoster virus (VZV), which was a significant root cause of corneal ailment and vision loss across the globe.1,5 Intermittent disease, stromal irritation, and neuro-ophthalmic complexities promote substantially extended visual disability.1,4,5 Enhanced outcomes were seen through several advances in antiviral therapy, molecular diagnostics and interventional pain management. So far, challenges remain periodic in antiviral resistance and post-therapeutic neuralgia.1–3,8 This study integrates the documentation from ten associates who evaluated the research studies published in Elsevier, ScienceDirect- listed journals, to give a detailed summary of epidemiology, pathophysiology, diagnostic procedures, clinical profile, therapeutic strategies, and drawbacks of ocular herpes.1–10 Long-term antiviral prevention, statistical PCR-based diagnostics, management of herpes zoster ophthalmicus, and developing advancements for unmanageable pain and unusual complications are more prominent.1–3,5,8–10
*Momina Shaik, Sai Sri Kalam, Himaja Kumari Ponnada, Adi Praneeth Appikonda (Sun,) studied this question.